| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/06/2010 | EP2139480A1 Ranolazine for enhancing insulin secretion |
| 01/06/2010 | EP2139338A2 Compositions and methods for cell killing |
| 01/06/2010 | EP1742624B1 Dopamine-agonist combination therapy with sedatives for improving sleep quality |
| 01/06/2010 | EP1687015B1 Compositions for the treatment of diseases of the oral cavity and upper respiratory tract |
| 01/06/2010 | EP1427713B1 Benzothiazepine derivatives for the treatment of hyperlipidemia |
| 01/06/2010 | EP1005361B1 USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY |
| 01/06/2010 | EP0963197B1 Guanylhydrazones useful for treating diseases associated with t cell activation |
| 01/06/2010 | CN101622015A Pharmaceutical composition |
| 01/06/2010 | CN101622014A Improved medicinal compositions comprising buprenorphine and naltrexone |
| 01/06/2010 | CN101622013A Improved medicinal compositions comprising buprenorphine and naloxone |
| 01/06/2010 | CN101622012A Improved medicinal compositions comprising buprenorphine and nalmefene |
| 01/06/2010 | CN101618216A Direct compression formulation and process |
| 01/06/2010 | CN101618215A Pharmaceutical composition containing calcium blocker, AII receptor blocker and statins |
| 01/06/2010 | CN101618214A Medicine target point for treating friable X syndrome and application thereof in pharmacy |
| 01/06/2010 | CN100578227C TTK in diagnosis and as a therapeutic target in cancer |
| 01/06/2010 | CN100577206C Controlled release composition and method of producing the same |
| 01/06/2010 | CN100577175C Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| 01/06/2010 | CN100577174C Compositions containing defined oxidized phospholipids |
| 01/06/2010 | CN100577162C Substituted oxazolidinones for combinational therapy |
| 01/05/2010 | US7642358 Antidiabetic agents; modulate insulin drug resistance |
| 01/05/2010 | US7642286 Stable pharmaceutical compositions containing pravastatin |
| 01/05/2010 | US7642243 Administering C-type natriuretic peptide, guanyl cyclase (GC-B)-activating peptide |
| 01/05/2010 | US7642229 Synergistic antineoplastic effect; side effect reduction |
| 01/05/2010 | US7642051 Induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (also called adenine nucleotide translocase or ADP/ATP carrier) |
| 01/05/2010 | US7641906 Intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis |
| 01/05/2010 | US7641901 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 01/05/2010 | US7641898 cells are dispersed using an air-jet sprayer after being suspended in a soluble media either directly onto the area or onto a tissue scaffold to form three dimensional epithelial tissue |
| 01/05/2010 | US7641894 Stimulating neutrophil function to treat inflammatory bowel disease |
| 01/05/2010 | US7641643 Methods and compositions to treat myocardial conditions |
| 01/05/2010 | CA2449098C Pharmaceutical compositions for the coordinated delivery of nsaids |
| 01/05/2010 | CA2429162C Methods and compositions for enhancing cellular function through protection of tissue components |
| 01/05/2010 | CA2426457C Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 01/05/2010 | CA2424512C Delivery system and method of treating or preventing otitis media |
| 01/05/2010 | CA2390100C Diaryl piperidyl pyrrole derivatives as antiprotozoal agents |
| 01/05/2010 | CA2368583C New medicament compositions based on anticholinergically-effective compounds and .beta.-mimetics |
| 01/05/2010 | CA2358948C Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 01/05/2010 | CA2355584C Intraoral adhesive preparation |
| 01/05/2010 | CA2332642C Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means |
| 01/05/2010 | CA2322168C Method for treating painful conditions of the anal region and compositions therefor |
| 01/05/2010 | CA2318192C .beta.2-adrenergic receptor agonists |
| 01/05/2010 | CA2236023C Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same |
| 12/31/2009 | US20090326218 Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents |
| 12/31/2009 | US20090326052 Promoters exhibiting endothelial cell specificity and methods of using same |
| 12/31/2009 | US20090326047 Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| 12/31/2009 | US20090326038 Method for treating a immunology-related disease |
| 12/31/2009 | US20090326026 Tricyclic Compounds Useful as Angiotensin II Agonists |
| 12/31/2009 | US20090325878 Organ preconditioning, arrest, protection, preservation and recovery |
| 12/31/2009 | US20090324758 Plant extract mixtures and their uses |
| 12/31/2009 | US20090324744 Effective Antitumor Treatments |
| 12/31/2009 | US20090324632 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 12/31/2009 | US20090324599 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity |
| 12/31/2009 | US20090324583 Methods for inducing the differentiation of hematopoietic stem cells into megakaryocytes and platelets, and gene controlling the differentiation |
| 12/31/2009 | US20090324577 6-11 Bicyclic Ketolide Derivatives |
| 12/31/2009 | US20090324566 T-Cell Receptor and Nucliec Acid Encoding the Receptor |
| 12/31/2009 | US20090324559 Methods and platforms for drug discovery |
| 12/31/2009 | US20090324551 Tlr agonists |
| 12/31/2009 | US20090324542 optic neuritis; fingolimod or 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol or salts as SP1 agonist |
| 12/31/2009 | DE102008040042A1 Microparticle, useful in the diagnosis or therapy of e.g. tumors, metabolic diseases, comprises an aggregate from superparamagnetic nanoparticle, where the nanoparticle exists alone or in combination with an active agent, e.g. antibody |
| 12/31/2009 | CA2724607A1 Method and composition for skin inflammation and discoloration |
| 12/30/2009 | WO2009158384A1 Methods and kits for the treatment inhibition, and maintenance of gastrointestinal disorders |
| 12/30/2009 | WO2009158144A1 Method and composition for dermatoses |
| 12/30/2009 | WO2009156680A2 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders |
| 12/30/2009 | WO2009155962A1 Use |
| 12/30/2009 | WO2009133141A3 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis |
| 12/30/2009 | WO2009129187A3 Combination therapy for glaucoma |
| 12/30/2009 | WO2009117740A3 Treatment of intervertebral disc degeneration |
| 12/30/2009 | WO2009080808A3 Pharmaceutical for the treatment of fibrosing pulmonary diseases |
| 12/30/2009 | WO2008156807A3 Antithrombotic agents and methods of use thereof |
| 12/30/2009 | EP2138189A1 Synergistic microbicidal compositions |
| 12/30/2009 | EP2138188A1 Combinations comprising antimuscarinic agents and beta-adrenergic agonists |
| 12/30/2009 | EP2138179A1 Use of cytidine derivatives for the treatment of leukaemia |
| 12/30/2009 | EP2138175A2 Formulations comprising valsartan for treating diabetes or microalbuminuria |
| 12/30/2009 | EP2138174A1 Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management |
| 12/30/2009 | EP2138170A2 Prevention and Treatment of Oxidative Stress Disorders by compounds which elevate intracellular levels of glutathione or Phase II Detoxification Enzymes |
| 12/30/2009 | EP2138055A1 Formula food to be beneficial for visuognosis persistence and use thereof |
| 12/30/2009 | EP2136843A1 Biomarkers of prostate cancer and uses thereof |
| 12/30/2009 | EP2136842A1 Combination of progesterone-receptor antagonist together with an aromatase inhibitor for prophylaxis or treatment of brca mediated diseases |
| 12/30/2009 | EP2136816A2 Oleyl phosphocholine |
| 12/30/2009 | EP2136780A1 Use of ranolazine for the treatment of cardiovascular diseases |
| 12/30/2009 | EP1501498B1 Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| 12/30/2009 | EP1470239B1 Psoriasin expression by breast epithelial cells |
| 12/30/2009 | EP1448565B1 ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 12/30/2009 | EP1307108B1 Oil/fat composition |
| 12/30/2009 | EP0863754B2 Hydrolysis-optimized lipid emulsions and use thereof |
| 12/30/2009 | CN101613688A Von willebrand factor (vWF)-cleaving protease |
| 12/30/2009 | CN101613321A Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| 12/30/2009 | CN101612403A Medicinal composition containing calcium channel blockers, ACE inhibitors and statins |
| 12/30/2009 | CN101612402A Interferon antagonist and use of Flt3L interferon |
| 12/30/2009 | CN101612401A Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 12/30/2009 | CN101612400A Application of 1 type receptor antagonist of angiotensin II in treating tumour |
| 12/30/2009 | CN100574804C A composition for treating gastrointestinal disorder |
| 12/30/2009 | CN100574803C Use of immunoregulation antibody for the treatment of neoplastic disorders |
| 12/30/2009 | CN100574753C Medicinal salt with local narcosis and antiphlogosis activity and its preparation process |
| 12/30/2009 | CN100574750C Rapidly-disintegrating formulation for releasing active ingredients |
| 12/30/2009 | CA2729034A1 Use |
| 12/29/2009 | US7638620 Use to enhance apoptosis; antiproliferative agents |
| 12/29/2009 | US7638601 Transient receptor potential channel TRPM8 and its use |
| 12/29/2009 | US7638598 ErbB interface peptidomimetics and methods of use thereof |
| 12/29/2009 | US7638555 hydrolyzing titanium alkoxide in a reverse micelle solution of highly-dispersed nano-droplets of an organic continuous phase, a nonionic surfactant, and water to form a TiO2-containing solution; dip coating it on a substrate; drying and calcining; used for for killing bacteria and viruses in UV radiation |
| 12/29/2009 | US7638551 Amino alcohol compounds or phosphonic acid derivatives thereof |